Terms: = Prostate cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Diagnosis
64 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. Oncocytoid Salivary Tumors: Differential diagnosis and Utility of Newly Described Immunohistochemistry.
Katabi N
Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
[TBL] [Abstract] [Full Text] [Related]
3. The role of area-level socioeconomic disadvantage in racial disparities in cancer incidence in metropolitan Detroit.
Purrington KS; Hastert TA; Madhav KC; Nair M; Snider N; Ruterbusch JJ; Schwartz AG; Stoffel EM; Peters ES; Rozek LS
Cancer Med; 2023 Jul; 12(13):14623-14635. PubMed ID: 37184135
[TBL] [Abstract] [Full Text] [Related]
4. Incidental diagnosis of Metastatic Breast cancer in a Man With 99m Tc-PSMA SPECT/CT.
Zárate-García CD; Cardoza-Ochoa DR; Sánchez-Vera Y; González-Díaz JI
Clin Nucl Med; 2023 Apr; 48(4):e163-e164. PubMed ID: 36728144
[TBL] [Abstract] [Full Text] [Related]
5. Choice of Survival Metric and Its Impacts on cancer Survival Estimates for American Indian and Alaska Native People.
Nash SH; Wahlen MM; Meisner ALW; Morawski BM
Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):398-405. PubMed ID: 36723409
[TBL] [Abstract] [Full Text] [Related]
6. Expression of her2/neu in newly diagnosed metastatic carcinoma prostate on TRUS biopsy specimen and its clinical correlation and progression.
Abhishek A; Sarkar D; Kumar Pal D
Urologia; 2023 May; 90(2):244-247. PubMed ID: 36000702
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
Zang F; Ding X; Chen J; Hu L; Sun J; Zhang J; Xu Y; Yao L; Xie Y
Breast Cancer Res Treat; 2022 Oct; 195(3):431-439. PubMed ID: 35974241
[TBL] [Abstract] [Full Text] [Related]
8. "PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody": Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of erbb2-Overexpressing Gastric cancer Cells.
Zhou H; Liu H; Zhang Y; Xin Y; Huang C; Li M; Zhao X; Ding P; Liu Z
Drug Des Devel Ther; 2022; 16():1515-1530. PubMed ID: 35611358
[TBL] [Abstract] [Full Text] [Related]
9. Androgen Receptor as an Emerging Feasible Biomarker for Breast cancer.
You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
[TBL] [Abstract] [Full Text] [Related]
10. UpFrontPSMA: a randomized phase 2 study of sequential
Dhiantravan N; Emmett L; Joshua AM; Pattison DA; Francis RJ; Williams S; Sandhu S; Davis ID; Vela I; Neha N; Bressel M; Murphy DG; Hofman MS; Azad AA
BJU Int; 2021 Sep; 128(3):331-342. PubMed ID: 33682320
[TBL] [Abstract] [Full Text] [Related]
11. Facile fluorescent aptasensor using aggregation-induced emission luminogens for exosomal proteins profiling towards liquid biopsy.
Li B; Liu C; Pan W; Shen J; Guo J; Luo T; Feng J; Situ B; An T; Zhang Y; Zheng L
Biosens Bioelectron; 2020 Nov; 168():112520. PubMed ID: 32866725
[TBL] [Abstract] [Full Text] [Related]
12. The Benefits of Adjuvant Trastuzumab for her-2-Positive Salivary Gland cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract] [Full Text] [Related]
13. Epidemiology and biological characteristics of male breast cancer in Italy.
Mangone L; Ferrari F; Mancuso P; Carrozzi G; Michiara M; Falcini F; Piffer S; Filiberti RA; Caldarella A; Vitale F; Tumino R; Brustolin A; Tagliabue G; Giorgi Rossi P; Ottini L
Breast Cancer; 2020 Jul; 27(4):724-731. PubMed ID: 32114665
[TBL] [Abstract] [Full Text] [Related]
14. Detection of a prostate cancer cell line using a bioluminescent affiprobe: An attempt to develop a new molecular probe for ex vivo studies.
Varnosfaderani ZG; Emamzadeh R; Nazari M; Zarean M
Int J Biol Macromol; 2019 Oct; 138():755-763. PubMed ID: 31306701
[TBL] [Abstract] [Full Text] [Related]
15. Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United States.
Shabihkhani M; Patil P; Murati Amador B; Plaza JA; Osunkoya AO; Lombardo KA; Epstein JI; Matoso A
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):524-531. PubMed ID: 31290785
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract] [Full Text] [Related]
17. Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era.
Zhang L; Yu X; Zhou L; Yang Y; Liu S
J BUON; 2018; 23(5):1316-1324. PubMed ID: 30570853
[TBL] [Abstract] [Full Text] [Related]
18. [A Case of Synchronous Quadruple cancers Treated with Neoadjuvant Chemotherapy Followed by Surgery].
Muramoto K; Miyake T; Shimizu T; Sonoda H; Ueki T; Terada Y; Mori H; Maehira H; Takebayashi K; Kaida S; Iida H; Yamaguchi T; Tani M
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1871-1873. PubMed ID: 29394804
[TBL] [Abstract] [Full Text] [Related]
19. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Karow DS; Mills IG; Andreassen OA; Dale AM;
BMJ; 2018 Jan; 360():j5757. PubMed ID: 29321194
[TBL] [Abstract] [Full Text] [Related]
20. Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and diagnosis.
Grosset AA; Loayza-Vega K; Adam-Granger É; Birlea M; Gilks B; Nguyen B; Soucy G; Tran-Thanh D; Albadine R; Trudel D
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):558-563. PubMed ID: 29271792
[TBL] [Abstract] [Full Text] [Related]
[Next]
